Results from the randomized trial showed severe OM occurred in fewer than 10% of the cases tested with Cooral® System.
For patients with lymphoma, use of the Cooral®System showed vastly improved prevention of OM and was significantly more effective when compared to the conventional method with ice [Oral Mucositis Assessment Scale (OMAS) mean total 1.77 vs 3.08; p = 0.047].
As for patient-reported tolerability, both diagnostic groups (myeloma and lymphoma), reported a statistically significant higher degree of tolerability when Cooral® was used as compared with Ice [p = 0.020].